Top ▲

Estrogen receptor-β

Click here for help

Target not currently curated in GtoImmuPdb

Target id: 621

Nomenclature: Estrogen receptor-β

Systematic Nomenclature: NR3A2

Family: 3A. Estrogen receptors

Gene and Protein Information Click here for help
Species AA Chromosomal Location Gene Symbol Gene Name Reference
Human 530 14q23.2-q23.3 ESR2 estrogen receptor 2 22
Mouse 530 12 33.52 cM Esr2 estrogen receptor 2 (beta) 33
Rat 530 6q24 Esr2 estrogen receptor 2 12
Previous and Unofficial Names Click here for help
Erb2 | nuclear receptor subfamily 3 group A member 2 | ERβ | Erb | Estrb | estrogen receptor 2 (ER beta)
Database Links Click here for help
CATH/Gene3D
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
Pharos
RefSeq Nucleotide
RefSeq Protein
SynPHARM
UniProtKB
Wikipedia
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  Estrogen receptor beta-ligand-binding domain
PDB Id:  1L2J
Ligand:  R,R-THC
Resolution:  2.95Å
Species:  Human
References:  29
Natural/Endogenous Ligands Click here for help
17β-estradiol
estrone

Download all structure-activity data for this target as a CSV file go icon to follow link

Agonists Click here for help
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
diethylstilbestrol Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 9.8 pKi 11
pKi 9.8 [11]
17β-estradiol Small molecule or natural product Approved drug Click here for species-specific activity table Ligand is endogenous in the given species Ligand has a PDB structure Hs Agonist 9.3 pKi 11
pKi 9.3 [11]
diarylpropionitrile Small molecule or natural product Click here for species-specific activity table Hs Agonist 8.6 pKi 19,30
pKi 8.6 [19,30]
estriol Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 8.4 pKi 11
pKi 8.4 [11]
genistein Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 8.2 pKi 11
pKi 8.2 [11]
FERb 033 Small molecule or natural product Primary target of this compound Hs Agonist 8.1 pKi 21
pKi 8.1 (Ki 7.1x10-9 M) [21]
estrone Small molecule or natural product Approved drug Click here for species-specific activity table Ligand is endogenous in the given species Ligand has a PDB structure Hs Agonist 7.9 pKi 11
pKi 7.9 [11]
tamoxifen Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 7.2 pKi 11
pKi 7.2 [11]
diarylpropionitrile Small molecule or natural product Primary target of this compound Click here for species-specific activity table Hs Agonist 9.1 pEC50 36
pEC50 9.1 (EC50 8.5x10-10 M) [36]
WAY200070 Small molecule or natural product Click here for species-specific activity table Hs Agonist 8.7 pEC50 9
pEC50 8.7 (EC50 2x10-9 M) [9]
FERb 033 Small molecule or natural product Hs Agonist 8.3 pEC50 21
pEC50 8.3 (EC50 4.8x10-9 M) [21]
AC-186 Small molecule or natural product Primary target of this compound Click here for species-specific activity table Hs Agonist 8.2 pEC50 16
pEC50 8.2 (EC50 6x10-9 M) [16]
Description: Measured using Receptor Selection and Amplification Technology (R-SAT).
norendoxifen Small molecule or natural product Click here for species-specific activity table Hs Agonist 7.6 pEC50 13
pEC50 7.6 (EC50 2.75x10-8 M) [13]
liquiritigenin Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Agonist 7.4 pEC50 17
pEC50 7.4 (EC50 3.65x10-8 M) [17]
Description: Measuring activation of the ERE tk-Luc reporter by ER&bets; in transfected U2OS cells.
bisphenol A Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Partial agonist 6.0 pEC50 15
pEC50 6.0 (EC50 1.1x10-6 M) [15]
WAY200070 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 8.5 – 9.0 pIC50 14
pIC50 8.5 – 9.0 (IC50 3x10-9 – 1x10-9 M) [14]
prinaberel Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Rn Agonist 8.5 pIC50 3
pIC50 8.5 (IC50 3.1x10-9 M) [3]
prinaberel Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Mm Agonist 8.4 pIC50 3
pIC50 8.4 (IC50 3.7x10-9 M) [3]
prinaberel Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 8.3 pIC50 3,14
pIC50 8.3 (IC50 5x10-9 M) [3,14]
ethinylestradiol Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 8.1 pIC50 10
pIC50 8.1 (IC50 8.1x10-9 M) [10]
lasofoxifene Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Partial agonist 7.9 pIC50 25
pIC50 7.9 (IC50 1.3x10-8 M) [25]
View species-specific agonist tables
Agonist Comments
Ethinyl estradiol is selective for estrogen receptor α, where its affinity is 2nM [10].
Antagonists Click here for help
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
4-hydroxytamoxifen Small molecule or natural product Click here for species-specific activity table Hs Antagonist 10.6 pKi 11
pKi 10.6 [11]
fulvestrant Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Antagonist 8.9 pKi 28
pKi 8.9 (Ki 1.39x10-9 M) [28]
R,R-THC Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 8.4 pKi 18,31
pKi 8.4 (Ki 3.6x10-9 M) [18,31]
raloxifene Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 8.0 pKi 8
pKi 8.0 (Ki 1x10-8 M) [8]
HPTE Small molecule or natural product Ligand has a PDB structure Hs Antagonist 7.6 pKi 5
pKi 7.6 [5]
tamoxifen Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 7.2 pKi 11
pKi 7.2 [11]
PHTPP Small molecule or natural product Hs Antagonist 6.9 pKi 37
pKi 6.9 (Ki 1.39x10-7 M) [37]
bazedoxifene Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 7.1 pIC50 20
pIC50 7.1 (IC50 8.5x10-8 M) [20]
DNA Binding Click here for help
Structure:  Homodimer
HRE core sequence:  GGTCAnnnTGACC
Response element:  ERE, Half site, Palindrome
Co-binding Partners Click here for help
Name Interaction Effect Reference
AP1 Physical, Functional Transcriptional activation 32
SP1 Physical, Functional DNA binding, Transcriptional activation 27
HSP90 Physical, Functional Cellular localization, DNA binding 4
Main Co-regulators Click here for help
Name Activity Specific Ligand dependent AF-2 dependent Comments References
NCOA1 Co-activator No Yes Yes 7
NCOA2 Co-activator No Yes Yes 7
NCOA3 Co-activator No Yes Yes 7
EP300 Co-activator No Yes Yes 7
CREBBP Co-activator No Yes Yes 7
MED1 Co-activator No Yes Yes 7
DDX5 Co-activator No Yes No 7
SRA1 Co-activator No Yes No 7
NCOR1 Co-repressor No Yes No 7
NRIP1 Co-repressor No Yes Yes Competes with AF-2 cofactor binding 7
Main Target Genes Click here for help
Name Species Effect Technique Comments References
TFF1 Human Activated ChIP, Transient transfection, EMSA 1
PGR Human Activated Footprint, Transient transfection,EMSA 24
LFT Human Activated Footprint, Transient transfection,ChIP 6
CTSD Human Activated Transient transfection, EMSA 35
Tissue Distribution Click here for help
Prostate, ovary, lungs, mammary gland, bone, uterus, epididymis, kidney, bladder, intestine, central, periferal nervous system
Species:  Human
Technique:  Northern, Q-PCR, In situ, Western, immunohistology
References: 
Functional Assays Click here for help
Ovulatory stimulation
Species:  Mouse
Tissue:  Ovarian, uterine
Response measured:  Defective ovulatory stimulation
References:  26
Physiological Consequences of Altering Gene Expression Click here for help
Knock-out mice show reduced fertility (female), prostate hyperplasia, disturbed neuronal migration in embryonic brain, myeloproliferative disease and hypertension
Species:  Mouse
Tissue: 
Technique:  Knockout
References:  34
Phenotypes, Alleles and Disease Models Click here for help Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0002182 abnormal astrocyte morphology PMID: 11226319 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0002458 abnormal B cell number PMID: 12603601 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0002458 abnormal B cell number PMID: 12603601 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0004924 abnormal behavior PMID: 19366879 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0000172 abnormal bone marrow cell number PMID: 12603601 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0000172 abnormal bone marrow cell number PMID: 12603601 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0002896 abnormal bone mineralization PMID: 15283680 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0004738 abnormal brainstem auditory evoked potential PMID: 18317592 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0005416 abnormal circulating protein level PMID: 10805804 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0004816 abnormal class switch recombination PMID: 12603601 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0004746 abnormal cochlear IHC afferent innervation pattern PMID: 12062753 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0003796 abnormal cortical bone morphology PMID: 15283680 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0003796 abnormal cortical bone morphology PMID: 10805804 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0009372 abnormal cumulus oophorus PMID: 9861029 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0008884 abnormal enterocyte apoptosis PMID: 16477031 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0000479 abnormal enterocyte morphology PMID: 16477031 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0008882 abnormal enterocyte physiology PMID: 16477031 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0008883 abnormal enterocyte proliferation PMID: 16477031 
Esr2tm1.2Pcn Esr2tm1.2Pcn/Esr2tm1.2Pcn
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MP:0001927 abnormal estrous cycle PMID: 18268329 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0002912 abnormal excitatory postsynaptic potential PMID: 16054246 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0008859 abnormal hair cycle catagen phase PMID: 15591132 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0002490 abnormal immunoglobulin level PMID: 12603601 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0006267 abnormal intercalated disc morphology PMID: 15375213 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0004842 abnormal large intestine crypts of Lieberkuhn morphology PMID: 16477031 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0005460 abnormal leukopoiesis PMID: 12740446 
Esr2tm1Unc|Inhatm1Bay Esr2tm1Unc/Esr2tm1Unc,Inhatm1Bay/Inhatm1Bay
involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd
MGI:109392  MGI:96569  MP:0000598 abnormal liver morphology PMID: 12855748 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0003055 abnormal long bone epiphyseal plate morphology PMID: 14753739 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0001175 abnormal lung morphology PMID: 12740446 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0002401 abnormal lymphopoiesis PMID: 12740446 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0009504 abnormal mammary gland epithelium morphology PMID: 12438700 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0006270 abnormal mammary gland growth during lactation PMID: 12438700 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0006269 abnormal mammary gland growth during pregnancy PMID: 12438700 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0005620 abnormal muscle contractility PMID: 15280152 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0004145 abnormal muscle electrophysiology PMID: 11799247 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0000278 abnormal myocardial fiber morphology PMID: 15375213 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0008547 abnormal neocortex morphology PMID: 11226319 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
B6.129P2-Esr2
MGI:109392  MP:0002736 abnormal nociception after inflammation PMID: 19285805 
Esr1tm1.1Mma|Esr2tm1Mma Esr1tm1.1Mma/Esr1tm1.1Mma,Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MGI:1352467  MP:0001131 abnormal ovarian follicle morphology PMID: 10976058 
Esr2tm1.2Pcn Esr2tm1.2Pcn/Esr2tm1.2Pcn
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MP:0001131 abnormal ovarian follicle morphology PMID: 18268329 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MGI:1352467  MP:0001126 abnormal ovary morphology PMID: 10600740 
Esr1tm1.1Mma|Esr2tm1Mma Esr1tm1.1Mma/Esr1tm1.1Mma,Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MGI:1352467  MP:0001126 abnormal ovary morphology PMID: 10976058 
Esr1tm1Ksk|Esr2tm1Unc|Inhatm1Bay Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc,Inhatm1Bay/Inhatm1Bay
involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd
MGI:109392  MGI:1352467  MGI:96569  MP:0001126 abnormal ovary morphology PMID: 12855748 
Esr1tm1Ksk|Esr2tm1Unc|Inha+|Inhatm1Bay Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc,Inhatm1Bay/Inha+
involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd
MGI:109392  MGI:1352467  MGI:96569  MP:0001126 abnormal ovary morphology PMID: 12855748 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0002270 abnormal respiratory alveoli morphology PMID: 14612399 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 11380688  12603601 
Esr1tm1.1Mma|Esr2tm1Mma Esr1tm1.1Mma/Esr1tm1.1Mma,Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MGI:1352467  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 10976058 
Esr1+|Esr1tm1.1Mma|Esr2tm1Mma Esr1tm1.1Mma/Esr1+,Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MGI:1352467  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 10976058 
Esr2tm1Mma Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas
MGI:109392  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 10976058 
Esr1tm1.1Mma|Esr2+|Esr2tm1Mma Esr1tm1.1Mma/Esr1tm1.1Mma,Esr2tm1Mma/Esr2+
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MGI:1352467  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 10976058 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 11557741  12603601 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 10927637 
Esr1tm1.1Mma|Esr2tm1Mma Esr1tm1.1Mma/Esr1tm1.1Mma,Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MGI:1352467  MP:0006416 abnormal rete testis morphology PMID: 10976058 
Esr1+|Esr1tm1.1Mma|Esr2tm1Mma Esr1tm1.1Mma/Esr1+,Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MGI:1352467  MP:0009363 abnormal secondary ovarian follicle morphology PMID: 10976058 
Esr1tm1.1Mma|Esr2tm1Mma Esr1tm1.1Mma/Esr1tm1.1Mma,Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MGI:1352467  MP:0002216 abnormal seminiferous tubule morphology PMID: 10976058 
Esr1tm1Ksk|Esr2tm1Unc|Inhatm1Bay Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc,Inhatm1Bay/Inhatm1Bay
involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd
MGI:109392  MGI:1352467  MGI:96569  MP:0002216 abnormal seminiferous tubule morphology PMID: 12855748 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
B6.129P2-Esr2
MGI:109392  MP:0005322 abnormal serotonin concentration PMID: 15642619 
Esr1tm1.1Mma|Esr2tm1Mma Esr1tm1.1Mma/Esr1tm1.1Mma,Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MGI:1352467  MP:0002784 abnormal Sertoli cell morphology PMID: 10976058 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0002566 abnormal sexual interaction PMID: 11114183 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0002566 abnormal sexual interaction PMID: 11114183 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0000859 abnormal somatosensory cortex morphology PMID: 11226319 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0001463 abnormal spatial learning PMID: 11891272 
Esr2tm1Unc|Inhatm1Bay Esr2tm1Unc/Esr2tm1Unc,Inhatm1Bay/Inhatm1Bay
involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd
MGI:109392  MGI:96569  MP:0000470 abnormal stomach morphology PMID: 12855748 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0000836 abnormal substantia nigra morphology PMID: 11226319 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0004782 abnormal surfactant physiology PMID: 14612399 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0000540 abnormal urinary bladder epithelium morphology PMID: 9861029 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0000540 abnormal urinary bladder epithelium morphology PMID: 17522255 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0000538 abnormal urinary bladder morphology PMID: 17522255 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0010386 abnormal urinary bladder physiology PMID: 17522255 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0009643 abnormal urine homeostasis PMID: 17522255 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0004903 abnormal uterus weight PMID: 11557741 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0005592 abnormal vascular smooth muscle morphology PMID: 11799247 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0005595 abnormal vascular smooth muscle physiology PMID: 11799247 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MGI:1352467  MP:0000137 abnormal vertebrae morphology PMID: 14753739 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MGI:1352467  MP:0001134 absent corpus luteum PMID: 10600740 
Esr1+|Esr1tm1.1Mma|Esr2tm1Mma Esr1tm1.1Mma/Esr1+,Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MGI:1352467  MP:0001134 absent corpus luteum PMID: 10976058 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0000392 accelerated hair follicle regression PMID: 15591132 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6
MGI:109392  MP:0004484 altered response of heart to induced stress PMID: 15698835 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0000343 altered response to myocardial infarction PMID: 15781739 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0001577 anemia PMID: 12740446 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0008869 anovulation PMID: 9861029 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0005324 ascites PMID: 15781739 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MGI:1352467  MP:0002675 asthenozoospermia PMID: 10600740 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0003354 astrocytosis PMID: 11226319 
Esr1tm1Ksk|Esr2tm1Unc|Inhatm1Bay Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc,Inhatm1Bay/Inhatm1Bay
involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd
MGI:109392  MGI:1352467  MGI:96569  MP:0005150 cachexia PMID: 12855748 
Esr2tm1Unc|Inhatm1Bay Esr2tm1Unc/Esr2tm1Unc,Inhatm1Bay/Inhatm1Bay
involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd
MGI:109392  MGI:96569  MP:0005150 cachexia PMID: 12855748 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0001625 cardiac hypertrophy PMID: 15375213 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0005481 chronic myelocytic leukemia PMID: 12740446 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0002816 colitis PMID: 16477031 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0003862 decreased aggression towards males PMID: 11114183 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0001262 decreased body weight PMID: 10805804 
Esr1tm1Ksk|Esr2tm1Unc|Inhatm1Bay Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc,Inhatm1Bay/Inhatm1Bay
involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd
MGI:109392  MGI:1352467  MGI:96569  MP:0001262 decreased body weight PMID: 12855748 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0010124 decreased bone mineral content PMID: 10805804 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0010121 decreased bone mineral density PMID: 10805804 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0000774 decreased brain size PMID: 11226319 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0008075 decreased CD4-positive T cell number PMID: 11380688 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0008079 decreased CD8-positive T cell number PMID: 11380688 
Esr1tm1Ksk|Esr2tm1Unc|Inhatm1Bay Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc,Inhatm1Bay/Inhatm1Bay
involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd
MGI:109392  MGI:1352467  MGI:96569  MP:0002790 decreased circulating follicle stimulating hormone level PMID: 12855748 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0005560 decreased circulating glucose level PMID: 19366879 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0004701 decreased circulating insulin-like growth factor I level PMID: 10805804 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0002680 decreased corpora lutea number PMID: 9861029 
Esr2tm1Mma Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas
MGI:109392  MP:0002680 decreased corpora lutea number PMID: 10976058 
Esr2tm1.2Pcn Esr2tm1.2Pcn/Esr2tm1.2Pcn
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MP:0002680 decreased corpora lutea number PMID: 18268329 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
B6.129P2-Esr2
MGI:109392  MP:0005643 decreased dopamine level PMID: 15642619 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
B6.129P2-Esr2
MGI:109392  MP:0001417 decreased exploration in new environment PMID: 15642619 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0003059 decreased insulin secretion PMID: 19366879 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0001935 decreased litter size PMID: 9861029 
Esr1tm1.1Mma|Esr2tm1Mma Esr1tm1.1Mma/Esr1tm1.1Mma,Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MGI:1352467  MP:0004901 decreased male germ cell number PMID: 10976058 
Esr1tm1Ksk|Esr2tm1Unc|Inhatm1Bay Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc,Inhatm1Bay/Inhatm1Bay
involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd
MGI:109392  MGI:1352467  MGI:96569  MP:0004901 decreased male germ cell number PMID: 12855748 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0008948 decreased neuron number PMID: 11226319 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0003355 decreased ovulation rate PMID: 9861029 
Esr2tm1.2Pcn Esr2tm1.2Pcn/Esr2tm1.2Pcn
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MP:0003355 decreased ovulation rate PMID: 18268329 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6
MGI:109392  MP:0008874 decreased physiological sensitivity to xenobiotic PMID: 15698835 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0004953 decreased spleen weight PMID: 11380688 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0004905 decreased uterus weight PMID: 11557741 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0008022 dilated heart ventricle PMID: 15375213 
Esr1tm1Ksk|Esr2tm1Unc|Inhatm1Bay Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc,Inhatm1Bay/Inhatm1Bay
involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd
MGI:109392  MGI:1352467  MGI:96569  MP:0009257 dilated seminiferous tubules PMID: 12855748 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0000274 enlarged heart PMID: 15375213 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0000599 enlarged liver PMID: 12740446 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0000702 enlarged lymph nodes PMID: 12740446 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0004564 enlarged myocardial fiber PMID: 15375213 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0009171 enlarged pancreatic islets PMID: 19366879 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0000691 enlarged spleen PMID: 12740446 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0009856 failure of ejaculation PMID: 11114183 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MGI:1352467  MP:0001926 female infertility PMID: 10600740 
Esr2tm1.2Pcn Esr2tm1.2Pcn/Esr2tm1.2Pcn
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MP:0001926 female infertility PMID: 18268329 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0003045 fibrosis PMID: 12740446 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
B6.129P2-Esr2
MGI:109392  MP:0005498 hyporesponsive to tactile stimuli PMID: 19285805 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0009454 impaired contextual conditioning behavior PMID: 16054246 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0009456 impaired cued conditioning behavior PMID: 16054246 
Esr1tm1.1Mma|Esr2tm1Mma Esr1tm1.1Mma/Esr1tm1.1Mma,Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MGI:1352467  MP:0003357 impaired granulosa cell differentiation PMID: 10976058 
Esr1+|Esr1tm1.1Mma|Esr2tm1Mma Esr1tm1.1Mma/Esr1+,Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MGI:1352467  MP:0003357 impaired granulosa cell differentiation PMID: 10976058 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0001129 impaired ovarian folliculogenesis PMID: 9861029 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0001356 increased aggression towards females PMID: 11114183 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0001354 increased aggression towards males PMID: 11114183 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
B6.129P2-Esr2
MGI:109392  MP:0001363 increased anxiety-related response PMID: 15642619 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MGI:1352467  MP:0001257 increased body length PMID: 14753739 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0001257 increased body length PMID: 14753739 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0001260 increased body weight PMID: 15781739 
Esr1tm1Ksk|Esr2tm1Unc|Inhatm1Bay Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc,Inhatm1Bay/Inhatm1Bay
involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd
MGI:109392  MGI:1352467  MGI:96569  MP:0001260 increased body weight PMID: 12855748 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0000321 increased bone marrow cell number PMID: 12740446 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0005178 increased circulating cholesterol level PMID: 11095962 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0005559 increased circulating glucose level PMID: 19366879 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0001556 increased circulating HDL cholesterol level PMID: 11095962 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0004702 increased circulating insulin-like growth factor I level PMID: 11380688 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0005669 increased circulating leptin level PMID: 11095962 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MGI:1352467  MP:0001751 increased circulating luteinizing hormone level PMID: 10600740 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6
MGI:109392  MP:0001751 increased circulating luteinizing hormone level PMID: 14583652 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0005091 increased double-positive T cell number PMID: 11380688 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0003131 increased erythrocyte cell number PMID: 12740446 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0009285 increased gonadal fat pad weight PMID: 11095962 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0000322 increased granulocyte number PMID: 12740446 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0002833 increased heart weight PMID: 15781739 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0002891 increased insulin sensitivity PMID: 19366879 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0009580 increased keratinocyte apoptosis PMID: 15591132 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0000218 increased leukocyte cell number PMID: 12740446 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0008254 increased megakaryocyte cell number PMID: 12740446 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0000220 increased monocyte cell number PMID: 12740446 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0000219 increased neutrophil cell number PMID: 12740446 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0004988 increased osteoblast cell number PMID: 15283680 
Esr1tm1Ksk|Esr2tm1Unc|Inhatm1Bay Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc,Inhatm1Bay/Inhatm1Bay
involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd
MGI:109392  MGI:1352467  MGI:96569  MP:0008000 increased ovary tumor incidence PMID: 12855748 
Esr1tm1Ksk|Esr2tm1Unc|Inha+|Inhatm1Bay Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc,Inhatm1Bay/Inha+
involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd
MGI:109392  MGI:1352467  MGI:96569  MP:0008000 increased ovary tumor incidence PMID: 12855748 
Esr2tm1Unc|Inhatm1Bay Esr2tm1Unc/Esr2tm1Unc,Inhatm1Bay/Inhatm1Bay
involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd
MGI:109392  MGI:96569  MP:0008000 increased ovary tumor incidence PMID: 12855748 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0003132 increased pre-B cell number PMID: 12740446 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0008186 increased pro-B cell number PMID: 12740446 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0009304 increased retroperitoneal fat pad weight PMID: 11095962 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0009763 increased sensitivity to induced morbidity/mortality PMID: 15781739 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0002842 increased systemic arterial blood pressure PMID: 11799247 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0010024 increased total body fat amount PMID: 11095962 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0003025 increased vasoconstriction PMID: 11799247 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0005590 increased vasodilation PMID: 10927637 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0005331 insulin resistance PMID: 11095962 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MGI:1352467  MP:0004348 long femur PMID: 14753739 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0004348 long femur PMID: 14753739 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MGI:1352467  MP:0001925 male infertility PMID: 10600740 
Esr1tm1.1Mma|Esr2tm1Mma Esr1tm1.1Mma/Esr1tm1.1Mma,Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MGI:1352467  MP:0001925 male infertility PMID: 10976058 
Esr2tm1.2Pcn Esr2tm1.2Pcn/Esr2tm1.2Pcn
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MP:0001925 male infertility PMID: 18268329 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0001884 mammary gland alveolar hyperplasia PMID: 12438700 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0003224 neuron degeneration PMID: 11226319 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0001261 obese PMID: 11095962 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MGI:1352467  MP:0002687 oligozoospermia PMID: 10600740 
Esr1tm1.1Mma|Esr2tm1Mma Esr1tm1.1Mma/Esr1tm1.1Mma,Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MGI:1352467  MP:0002016 ovary cysts PMID: 10976058 
Esr1tm1Ksk|Esr2tm1Unc|Inhatm1Bay Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc,Inhatm1Bay/Inhatm1Bay
involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd
MGI:109392  MGI:1352467  MGI:96569  MP:0002083 premature death PMID: 12855748 
Esr2tm1Unc|Inhatm1Bay Esr2tm1Unc/Esr2tm1Unc,Inhatm1Bay/Inhatm1Bay
involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd
MGI:109392  MGI:96569  MP:0002083 premature death PMID: 12855748 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0001167 prostate gland epithelial hyperplasia PMID: 9861029 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0001923 reduced female fertility PMID: 9861029 
Esr1+|Esr1tm1.1Mma|Esr2tm1Mma Esr1tm1.1Mma/Esr1+,Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MGI:1352467  MP:0001923 reduced female fertility PMID: 10976058 
Esr2tm1Mma Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas
MGI:109392  MP:0001923 reduced female fertility PMID: 10976058 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0001473 reduced long term potentiation PMID: 16054246 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0003109 short femur PMID: 10805804 
Esr1tm1.1Mma|Esr2tm1Mma Esr1tm1.1Mma/Esr1tm1.1Mma,Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MGI:1352467  MP:0008983 small vagina PMID: 10976058 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0000693 spleen hyperplasia PMID: 12740446 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0000694 spleen hypoplasia PMID: 11380688 
Esr1tm1Ksk|Esr2tm1Unc|Inhatm1Bay Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc,Inhatm1Bay/Inhatm1Bay
involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd
MGI:109392  MGI:1352467  MGI:96569  MP:0006262 testis tumor PMID: 12855748 
Esr2tm1Unc|Inhatm1Bay Esr2tm1Unc/Esr2tm1Unc,Inhatm1Bay/Inhatm1Bay
involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd
MGI:109392  MGI:96569  MP:0006262 testis tumor PMID: 12855748 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MP:0001218 thin epidermis PMID: 15591132 
Esr1tm1.1Mma|Esr2tm1Mma Esr1tm1.1Mma/Esr1tm1.1Mma,Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MGI:1352467  MP:0009081 thin uterus PMID: 10976058 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd * C57BL/6J
MGI:109392  MGI:1352467  MP:0001823 thymus hypoplasia PMID: 11380688 
Esr2tm1Unc Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MP:0009646 urinary bladder inflammation PMID: 17522255 
Esr1tm1Ksk|Esr2tm1Unc Esr1tm1Ksk/Esr1tm1Ksk,Esr2tm1Unc/Esr2tm1Unc
involves: 129P2/OlaHsd
MGI:109392  MGI:1352467  MP:0001121 uterus hypoplasia PMID: 10600740 
Esr1tm1.1Mma|Esr2tm1Mma Esr1tm1.1Mma/Esr1tm1.1Mma,Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MGI:1352467  MP:0001121 uterus hypoplasia PMID: 10976058 
Esr1tm1.1Mma|Esr2tm1Mma Esr1tm1.1Mma/Esr1tm1.1Mma,Esr2tm1Mma/Esr2tm1Mma
involves: 129S2/SvPas * C57BL/6 * SJL
MGI:109392  MGI:1352467  MP:0008984 vagina hypoplasia PMID: 10976058 
Biologically Significant Variants Click here for help
Type:  Splice variant
Species:  Human
Description:  ERbetaCX: produced by splicing of last exon. Changes the amino acid sequence. Much reduced ligand-binding
References:  23
Type:  Splice variant
Species:  Rat
Description:  ERbetaIns: Splice variant. 18 amino acids inserted between exons 5 and 6.
References:  2

References

Show »

1. Barkhem T, Haldosén LA, Gustafsson JA, Nilsson S. (2002) pS2 Gene expression in HepG2 cells: complex regulation through crosstalk between the estrogen receptor alpha, an estrogen-responsive element, and the activator protein 1 response element. Mol Pharmacol, 61 (6): 1273-83. [PMID:12021387]

2. Chu S, Fuller PJ. (1997) Identification of a splice variant of the rat estrogen receptor beta gene. Mol Cell Endocrinol, 132 (1-2): 195-9. [PMID:9324061]

3. Cvoro A, Tatomer D, Tee MK, Zogovic T, Harris HA, Leitman DC. (2008) Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes. J Immunol, 180 (1): 630-6. [PMID:18097065]

4. Devin-Leclerc J, Meng X, Delahaye F, Leclerc P, Baulieu EE, Catelli MG. (1998) Interaction and dissociation by ligands of estrogen receptor and Hsp90: the antiestrogen RU 58668 induces a protein synthesis-dependent clustering of the receptor in the cytoplasm. Mol Endocrinol, 12 (6): 842-54. [PMID:9626660]

5. Hall DA, Beresford IJ, Browning C, Giles H. (1999) Signalling by CXC-chemokine receptors 1 and 2 expressed in CHO cells: a comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPgammaS binding induced by IL-8 and GROalpha. Br J Pharmacol, 126 (3): 810-8. [PMID:10188995]

6. Hall JM, Korach KS. (2002) Analysis of the molecular mechanisms of human estrogen receptors alpha and beta reveals differential specificity in target promoter regulation by xenoestrogens. J Biol Chem, 277 (46): 44455-61. [PMID:12200415]

7. Hall JM, McDonnell DP. (2005) Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv, 5 (6): 343-57. [PMID:16394250]

8. Henke BR, Drewry DH, Jones SA, Stewart EL, Weaver SL, Wiethe RW. (2001) 2-Amino-4,6-diarylpyridines as novel ligands for the estrogen receptor. Bioorg Med Chem Lett, 11 (14): 1939-42. [PMID:11459665]

9. Hughes ZA, Liu F, Platt BJ, Dwyer JM, Pulicicchio CM, Zhang G, Schechter LE, Rosenzweig-Lipson S, Day M. (2008) WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent. Neuropharmacology, 54 (7): 1136-42. [PMID:18423777]

10. Jain N, Kanojia RM, Xu J, Jian-Zhong G, Pacia E, Lai MT, Du F, Musto A, Allan G, Hahn D et al.. (2006) Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness. J Med Chem, 49 (11): 3056-9. [PMID:16722623]

11. Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson JA. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology, 138 (3): 863-70. [PMID:9048584]

12. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA, 93 (12): 5925-30. [PMID:8650195]

13. Lv W, Liu J, Lu D, Flockhart DA, Cushman M. (2013) Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities. J Med Chem, 56 (11): 4611-8. [PMID:23731360]

14. Malamas MS, Manas ES, McDevitt RE, Gunawan I, Xu ZB, Collini MD, Miller CP, Dinh T, Henderson RA, Keith JC et al.. (2004) Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem, 47 (21): 5021-40. [PMID:15456246]

15. Maruyama K, Nakamura M, Tomoshige S, Sugita K, Makishima M, Hashimoto Y, Ishikawa M. (2013) Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ERα-selective antagonist. Bioorg Med Chem Lett, 23 (14): 4031-6. [PMID:23768907]

16. McFarland K, Price DL, Davis CN, Ma JN, Bonhaus DW, Burstein ES, Olsson R. (2013) AC-186, a selective nonsteroidal estrogen receptor β agonist, shows gender specific neuroprotection in a Parkinson's disease rat model. ACS Chem Neurosci, 4 (9): 1249-55. [PMID:23898966]

17. Mersereau JE, Levy N, Staub RE, Baggett S, Zogovic T, Zogric T, Chow S, Ricke WA, Tagliaferri M, Cohen I et al.. (2008) Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. Mol Cell Endocrinol, 283 (1-2): 49-57. [PMID:18177995]

18. Meyers MJ, Sun J, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA. (1999) Estrogen receptor subtype-selective ligands: asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl- 5,6,11, 12-tetrahydrochrysenes. J Med Chem, 42 (13): 2456-68. [PMID:10395487]

19. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, Katzenellenbogen JA. (2001) Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem, 44 (24): 4230-51. [PMID:11708925]

20. Miller CP, Collini MD, Tran BD, Harris HA, Kharode YP, Marzolf JT, Moran RA, Henderson RA, Bender RH, Unwalla RJ et al.. (2001) Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J Med Chem, 44 (11): 1654-7. [PMID:11356100]

21. Minutolo F, Bertini S, Granchi C, Marchitiello T, Prota G, Rapposelli S, Tuccinardi T, Martinelli A, Gunther JR, Carlson KE et al.. (2009) Structural evolutions of salicylaldoximes as selective agonists for estrogen receptor beta. J Med Chem, 52 (3): 858-67. [PMID:19128016]

22. Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y, Muramatsu M. (1998) The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun, 243 (1): 122-6. [PMID:9473491]

23. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M. (1998) Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human. Nucleic Acids Res, 26 (15): 3505-12. [PMID:9671811]

24. Petz LN, Ziegler YS, Schultz JR, Kim H, Kemper JK, Nardulli AM. (2004) Differential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sites. J Steroid Biochem Mol Biol, 88 (2): 113-22. [PMID:15084343]

25. Renaud J, Bischoff SF, Buhl T, Floersheim P, Fournier B, Geiser M, Halleux C, Kallen J, Keller H, Ramage P. (2005) Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands. J Med Chem, 48 (2): 364-79. [PMID:15658851]

26. Rosenfeld CS, Roberts RM, Lubahn DB. (2001) Estrogen receptor- and aromatase-deficient mice provide insight into the roles of estrogen within the ovary and uterus. Mol Reprod Dev, 59 (3): 336-46. [PMID:11424220]

27. Safe S. (2001) Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm, 62: 231-52. [PMID:11345900]

28. Schmidt JM, Mercure J, Tremblay GB, Pagé M, Kalbakji A, Feher M, Dunn-Dufault R, Peter MG, Redden PR. (2003) De novo design, synthesis, and evaluation of novel nonsteroidal phenanthrene ligands for the estrogen receptor. J Med Chem, 46 (8): 1408-18. [PMID:12672240]

29. Shiau AK, Barstad D, Radek JT, Meyers MJ, Nettles KW, Katzenellenbogen BS, Katzenellenbogen JA, Agard DA, Greene GL. (2002) Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol, 9 (5): 359-64. [PMID:11953755]

30. Stauffer SR, Coletta CJ, Tedesco R, Nishiguchi G, Carlson K, Sun J, Katzenellenbogen BS, Katzenellenbogen JA. (2000) Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem, 43 (26): 4934-47. [PMID:11150164]

31. Sun J, Meyers MJ, Fink BE, Rajendran R, Katzenellenbogen JA, Katzenellenbogen BS. (1999) Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology, 140 (2): 800-4. [PMID:9927308]

32. Teyssier C, Belguise K, Galtier F, Chalbos D. (2001) Characterization of the physical interaction between estrogen receptor alpha and JUN proteins. J Biol Chem, 276 (39): 36361-9. [PMID:11477071]

33. Tremblay GB, Tremblay A, Copeland NG, Gilbert DJ, Jenkins NA, Labrie F, Giguère V. (1997) Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol Endocrinol, 11 (3): 353-65. [PMID:9058381]

34. Walker VR, Korach KS. (2004) Estrogen receptor knockout mice as a model for endocrine research. ILAR J, 45 (4): 455-61. [PMID:15454684]

35. Wang F, Porter W, Xing W, Archer TK, Safe S. (1997) Identification of a functional imperfect estrogen-responsive element in the 5'-promoter region of the human cathepsin D gene. Biochemistry, 36 (25): 7793-801. [PMID:9201922]

36. Waters EM, Mitterling K, Spencer JL, Mazid S, McEwen BS, Milner TA. (2009) Estrogen receptor alpha and beta specific agonists regulate expression of synaptic proteins in rat hippocampus. Brain Res, 1290: 1-11. [PMID:19596275]

37. Zhou HB, Sheng S, Compton DR, Kim Y, Joachimiak A, Sharma S, Carlson KE, Katzenellenbogen BS, Nettles KW, Greene GL et al.. (2007) Structure-guided optimization of estrogen receptor binding affinity and antagonist potency of pyrazolopyrimidines with basic side chains. J Med Chem, 50 (2): 399-403. [PMID:17228884]

Contributors

Show »

How to cite this page